Skip to main content
Top
Published in: CNS Drugs 1/2010

01-01-2010 | Original Research Article

Factors Associated with Serious Adverse Reactions to Cholinesterase Inhibitors

A Study of Spontaneous Reporting

Authors: Dr Antoine Pariente, Dina Joseph-Reinette Sanctussy, Ghada Miremont-Salamé, Nicholas Moore, Françoise Haramburu, Annie Fourrier-Réglat

Published in: CNS Drugs | Issue 1/2010

Login to get access

Abstract

Background: Cholinesterase inhibitors are used in Alzheimer’s disease, mostly in elderly persons with co-morbidities and receiving co-medications that could increase the risk of serious adverse reactions.
Objective: To identify factors associated with serious adverse drug reactions (ADRs) in patients treated with cholinesterase inhibitors.
Methods: All ADRs associated with donepezil, rivastigmine or galantamine were identified in the French pharmacovigilance database, from the launching of these drugs to January 2007. Serious ADRs (SADRs) were those that led to death, hospitalization or prolongation of hospitalization, or that were life threatening. A multiple logistic regression analysis was used to identify factors associated with seriousness in the reported adverse reactions.
Results: We identified 773 reports of ADRs related to cholinesterase inhibitor use, among which 438 (57%) concerned SADRs. The median age of patients was 80 years (interquartile range: 75–84 years); 65.1% were women. The most represented ADRs were those responsible for CNS disorders (17.0%), gastrointestinal disorders (16.2%) and cardiac rhythm disorders (11.2%). Factors associated with an increased risk of SADRs were: age (odds ratio [OR] 1.92; 95% CI 1.22, 3.02 for subjects aged 85 years and over), use of atypical antipsychotics (OR 2.15; 95% CI 1.04, 4.46), use of conventional antipsychotics (OR 2.06, 95% CI 1.10, 3.85), use of antihypertensive drugs (OR 2.11; 95% CI 1.47, 3.02) and use of drugs targeting the alimentary tract and metabolism (OR 1.62; 95% CI 1.06, 2.46). The use of benzodiazepines (long-acting or others), antidepressants (tricyclic or others) or antiarrhythmic drugs was not associated with the reporting of SADRs.
Conclusions: An increased risk of SADRs related to cholinesterase inhibitors was associated with the use of antipsychotics (with no difference between conventional and atypical antipsychotics), drugs targeting the alimentary tract/metabolism and antihypertensive drugs. It was not associated with the use of other psychotropic drugs, other non-psychotropic CNS drugs or with the use of antiarrhythmic agents. The association with drugs targeting the alimentary tract and metabolism could result from a protopathic bias or reflect the particular sensitivity to serious nausea and vomiting in patients already treated for gastrointestinal disorders. These results confirm that attention needs to be paid to patients receiving both cholinesterase inhibitors and antipsychotics.
Literature
1.
go back to reference Farlow MR, Cummings JL. Effective pharmacologic management of Alzheimer’s disease. Am J Med 2007 May; 120(5): 388–97PubMedCrossRef Farlow MR, Cummings JL. Effective pharmacologic management of Alzheimer’s disease. Am J Med 2007 May; 120(5): 388–97PubMedCrossRef
2.
go back to reference Bond J, Stave C, Sganga A, et al. Inequalities in dementia care across Europe: key findings of the Facing Dementia Survey. Int J Clin Pract Suppl 2005 Mar; (146): 8–14 Bond J, Stave C, Sganga A, et al. Inequalities in dementia care across Europe: key findings of the Facing Dementia Survey. Int J Clin Pract Suppl 2005 Mar; (146): 8–14
3.
go back to reference Gruber-Baldini AL, Stuart B, Zuckerman IH, et al. Treatment of dementia in community-dwelling and institutionalized medicare beneficiaries. J Am Geriatr Soc 2007 Oct; 55(10): 1508–16PubMedCrossRef Gruber-Baldini AL, Stuart B, Zuckerman IH, et al. Treatment of dementia in community-dwelling and institutionalized medicare beneficiaries. J Am Geriatr Soc 2007 Oct; 55(10): 1508–16PubMedCrossRef
4.
go back to reference Herrmann N, Gill SS, Bell CM, et al. A population-based study of cholinesterase inhibitor use for dementia. J Am Geriatr Soc 2007 Oct; 55(10): 1517–23PubMedCrossRef Herrmann N, Gill SS, Bell CM, et al. A population-based study of cholinesterase inhibitor use for dementia. J Am Geriatr Soc 2007 Oct; 55(10): 1517–23PubMedCrossRef
5.
go back to reference Pariente A, Helmer C, Fourrier A, et al. Prevalence of drug treatment in subjects with dementia in Europe. Pharmacoepidemiol Drug Saf 2008; 17(7): 655–60PubMedCrossRef Pariente A, Helmer C, Fourrier A, et al. Prevalence of drug treatment in subjects with dementia in Europe. Pharmacoepidemiol Drug Saf 2008; 17(7): 655–60PubMedCrossRef
6.
go back to reference Purandare N, Swarbrick C, Fischer A, et al. Cholinesterase inhibitors for Alzheimer’s disease: variations in clinical practice in the north-west of England. Int J Geriatr Psychiatry 2006 Oct; 21(10): 961–4PubMedCrossRef Purandare N, Swarbrick C, Fischer A, et al. Cholinesterase inhibitors for Alzheimer’s disease: variations in clinical practice in the north-west of England. Int J Geriatr Psychiatry 2006 Oct; 21(10): 961–4PubMedCrossRef
7.
go back to reference Kaduszkiewicz H, Zimmerman T, Beck-Bornholdt HP, et al. Cholinesterase inhibitors for patients with Alzheimer’s disease: systematic review of randomized clinical trials. BMJ 2005 Aug; 331(7512): 321–7PubMedCrossRef Kaduszkiewicz H, Zimmerman T, Beck-Bornholdt HP, et al. Cholinesterase inhibitors for patients with Alzheimer’s disease: systematic review of randomized clinical trials. BMJ 2005 Aug; 331(7512): 321–7PubMedCrossRef
8.
go back to reference Birks J. Cholinesterase inhibitors for Alzheimer’s disease. Cochrane Database Syst Rev 2006; (1): CD005593 Birks J. Cholinesterase inhibitors for Alzheimer’s disease. Cochrane Database Syst Rev 2006; (1): CD005593
9.
go back to reference Ferreri F, Agbokou C, Gauthier S. Cardiovascular effects of cholinesterase inhibitors in Alzheimer’s disease. Rev Neurol (Paris) 2007 Oct; 163(10): 968–74CrossRef Ferreri F, Agbokou C, Gauthier S. Cardiovascular effects of cholinesterase inhibitors in Alzheimer’s disease. Rev Neurol (Paris) 2007 Oct; 163(10): 968–74CrossRef
10.
go back to reference Sener S, Ozsarac M. Case of the month: rivastigmine (Exelon) toxicity with evidence of respiratory depression. Emerg Med J 2006 Jan; 23(1): 82–5PubMedCrossRef Sener S, Ozsarac M. Case of the month: rivastigmine (Exelon) toxicity with evidence of respiratory depression. Emerg Med J 2006 Jan; 23(1): 82–5PubMedCrossRef
11.
go back to reference Malone DM, Lindesay J. Cholinesterase inhibitors and cardiovascular disease: a survey of old age psychiatrists’ practice. Age Ageing 2007 May; 36(3): 331–3PubMedCrossRef Malone DM, Lindesay J. Cholinesterase inhibitors and cardiovascular disease: a survey of old age psychiatrists’ practice. Age Ageing 2007 May; 36(3): 331–3PubMedCrossRef
12.
go back to reference Gholami K, Shalviri G. Factors associated with preventability, predictability, and severity of adverse drug reactions. Ann Pharmacother 1999 Feb; 33(2): 236–40PubMedCrossRef Gholami K, Shalviri G. Factors associated with preventability, predictability, and severity of adverse drug reactions. Ann Pharmacother 1999 Feb; 33(2): 236–40PubMedCrossRef
13.
go back to reference Dormann H, Krebs S, Muth-Selbach U, et al. Adverse drug reactions in patients with gastroenterological diseases: does age increase the risk? Aliment Pharmacol Ther 2001 Feb; 15(2): 171–80PubMedCrossRef Dormann H, Krebs S, Muth-Selbach U, et al. Adverse drug reactions in patients with gastroenterological diseases: does age increase the risk? Aliment Pharmacol Ther 2001 Feb; 15(2): 171–80PubMedCrossRef
14.
go back to reference Quinn K, Baker MJ, Evans B. A population-wide profile of prescription drug use in Saskatchewan, 1989. CMAJ 1992 Jun 15; 146(12): 2177–86PubMed Quinn K, Baker MJ, Evans B. A population-wide profile of prescription drug use in Saskatchewan, 1989. CMAJ 1992 Jun 15; 146(12): 2177–86PubMed
15.
go back to reference Lagnaoui R, Depont F, Fourrier A, et al. Patterns and correlates of benzodiazepine use in the French general population. Eur J Clin Pharmacol 2004 Sep; 60(7): 523–9PubMedCrossRef Lagnaoui R, Depont F, Fourrier A, et al. Patterns and correlates of benzodiazepine use in the French general population. Eur J Clin Pharmacol 2004 Sep; 60(7): 523–9PubMedCrossRef
16.
go back to reference Tavassoli N, Sommet A, Lapeyre-Mestre M, et al. Drug interactions with cholinesterase inhibitors: an analysis of the French pharmacovigilance database and a comparison of two national drug formularies (Vidal, British National Formulary). Drug Saf 2007; 30(11): 1063–71PubMedCrossRef Tavassoli N, Sommet A, Lapeyre-Mestre M, et al. Drug interactions with cholinesterase inhibitors: an analysis of the French pharmacovigilance database and a comparison of two national drug formularies (Vidal, British National Formulary). Drug Saf 2007; 30(11): 1063–71PubMedCrossRef
17.
go back to reference Moore N, Biour M, Paux G, et al. Adverse drug reaction monitoring: doing it the French way. Lancet 1985; 2(8463): 1056–8PubMedCrossRef Moore N, Biour M, Paux G, et al. Adverse drug reaction monitoring: doing it the French way. Lancet 1985; 2(8463): 1056–8PubMedCrossRef
18.
go back to reference Moore N, Noblet C, Kreft-Jais C, et al. French pharmacovigilance database system: examples of utilization [in French]. Therapie 1995; 50(6): 557–62PubMed Moore N, Noblet C, Kreft-Jais C, et al. French pharmacovigilance database system: examples of utilization [in French]. Therapie 1995; 50(6): 557–62PubMed
21.
go back to reference Begaud B, Evreux JC, Jouglard J, et al. Imputation of the unexpected or toxic effects of drugs: actualization of the method used in France [in French]. Therapie 1985 Mar–Apr; 40(2): 111–8PubMed Begaud B, Evreux JC, Jouglard J, et al. Imputation of the unexpected or toxic effects of drugs: actualization of the method used in France [in French]. Therapie 1985 Mar–Apr; 40(2): 111–8PubMed
22.
go back to reference Council for International Organizations of Medical Sciences. Basic requirements for the use of terms for reporting adverse drug reactions. Pharmacoepidemiol Drug Saf 1992; 1: 39–45CrossRef Council for International Organizations of Medical Sciences. Basic requirements for the use of terms for reporting adverse drug reactions. Pharmacoepidemiol Drug Saf 1992; 1: 39–45CrossRef
23.
go back to reference Brodaty H, Ames D, Snowdon J, et al. A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. J Clin Psychiatry 2003 Feb; 64(2): 134–43PubMedCrossRef Brodaty H, Ames D, Snowdon J, et al. A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. J Clin Psychiatry 2003 Feb; 64(2): 134–43PubMedCrossRef
24.
go back to reference Conforti A, Chiamulera C, Moretti U, et al. Musculoskeletal adverse drug reactions: a review of literature and data from ADR spontaneous reporting databases. Curr Drug Saf 2007 Jan; 2(1): 47–63PubMedCrossRef Conforti A, Chiamulera C, Moretti U, et al. Musculoskeletal adverse drug reactions: a review of literature and data from ADR spontaneous reporting databases. Curr Drug Saf 2007 Jan; 2(1): 47–63PubMedCrossRef
25.
go back to reference Douglas IJ, Smeeth L. Exposure to antipsychotics and risk of stroke: self controlled case series study. BMJ 2008; 337: a1227PubMedCrossRef Douglas IJ, Smeeth L. Exposure to antipsychotics and risk of stroke: self controlled case series study. BMJ 2008; 337: a1227PubMedCrossRef
26.
go back to reference Gill SS, Rochon PA, Herrmann N, et al. Atypical antipsychotic drugs and risk of ischaemic stroke: population based retrospective cohort study. BMJ 2005 Feb 26; 330(7489): 445–8PubMedCrossRef Gill SS, Rochon PA, Herrmann N, et al. Atypical antipsychotic drugs and risk of ischaemic stroke: population based retrospective cohort study. BMJ 2005 Feb 26; 330(7489): 445–8PubMedCrossRef
27.
28.
go back to reference Knol W, van Marum RJ, Jansen PA, et al. Antipsychotic drug use and risk of pneumonia in elderly people. J Am Geriatr Soc 2008 Apr; 56(4): 661–6PubMedCrossRef Knol W, van Marum RJ, Jansen PA, et al. Antipsychotic drug use and risk of pneumonia in elderly people. J Am Geriatr Soc 2008 Apr; 56(4): 661–6PubMedCrossRef
29.
go back to reference Trifiro G, Verhamme KM, Ziere G, et al. All-cause mortality associated with atypical and typical antipsychotics in demented outpatients. Pharmacoepidemiol Drug Saf 2007 May; 16(5): 538–44PubMedCrossRef Trifiro G, Verhamme KM, Ziere G, et al. All-cause mortality associated with atypical and typical antipsychotics in demented outpatients. Pharmacoepidemiol Drug Saf 2007 May; 16(5): 538–44PubMedCrossRef
30.
go back to reference Warnock JK, Morris DW. Adverse cutaneous reactions to antipsychotics. Am J Clin Dermatol 2002; 3(9): 629–36PubMedCrossRef Warnock JK, Morris DW. Adverse cutaneous reactions to antipsychotics. Am J Clin Dermatol 2002; 3(9): 629–36PubMedCrossRef
31.
go back to reference Camargo AL, Cardoso Ferreira MB, Heineck I. Adverse drug reactions: a cohort study in internal medicine units at a university hospital. Eur J Clin Pharmacol 2006 Feb; 62(2): 143–9PubMedCrossRef Camargo AL, Cardoso Ferreira MB, Heineck I. Adverse drug reactions: a cohort study in internal medicine units at a university hospital. Eur J Clin Pharmacol 2006 Feb; 62(2): 143–9PubMedCrossRef
32.
go back to reference Avorn J, Gurwitz J, Rochon PA. Principles of pharmacology. In: Cassell CK, Cohen HJ, Larson EB, et al., editors. Geriatric medicine. 4th ed. New York: Springer-Verlag, 2001 Avorn J, Gurwitz J, Rochon PA. Principles of pharmacology. In: Cassell CK, Cohen HJ, Larson EB, et al., editors. Geriatric medicine. 4th ed. New York: Springer-Verlag, 2001
Metadata
Title
Factors Associated with Serious Adverse Reactions to Cholinesterase Inhibitors
A Study of Spontaneous Reporting
Authors
Dr Antoine Pariente
Dina Joseph-Reinette Sanctussy
Ghada Miremont-Salamé
Nicholas Moore
Françoise Haramburu
Annie Fourrier-Réglat
Publication date
01-01-2010
Publisher
Springer International Publishing
Published in
CNS Drugs / Issue 1/2010
Print ISSN: 1172-7047
Electronic ISSN: 1179-1934
DOI
https://doi.org/10.2165/11530300-000000000-00000

Other articles of this Issue 1/2010

CNS Drugs 1/2010 Go to the issue

Adis Drug Evaluation

Blonanserin